| Year |
Citation |
Score |
| 2018 |
Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications. PMID 29522717 DOI: 10.1016/J.Bbrc.2018.03.028 |
0.654 |
|
| 2014 |
Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH. Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Analytical Chemistry. 86: 1760-6. PMID 24354295 DOI: 10.1021/Ac4036197 |
0.352 |
|
| 2013 |
Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Science International. 233: 416-22. PMID 24314548 DOI: 10.1016/J.Forsciint.2013.10.002 |
0.603 |
|
| 2013 |
Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Analytical Chemistry. 85: 9390-9. PMID 23987522 DOI: 10.1021/Ac4024704 |
0.365 |
|
| 2012 |
Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC. Effects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms. Cell Biology International. 36: 1171-83. PMID 22938397 DOI: 10.1042/Cbi20120134 |
0.715 |
|
| 2012 |
Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 2174-84. PMID 22904561 DOI: 10.1124/Dmd.112.047530 |
0.758 |
|
| 2012 |
Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies Neuropharmacology. 63: 905-915. PMID 22771770 DOI: 10.1016/J.Neuropharm.2012.06.046 |
0.61 |
|
| 2012 |
Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39: 234-43. PMID 22561602 DOI: 10.1016/J.Pnpbp.2012.04.017 |
0.333 |
|
| 2012 |
Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chemical Research in Toxicology. 25: 825-7. PMID 22404317 DOI: 10.1021/Tx3000472 |
0.761 |
|
| 2012 |
Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A. Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 139-56. PMID 21970716 DOI: 10.3109/00498254.2011.609570 |
0.752 |
|
| 2011 |
Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Molecular Interventions. 11: 36-51. PMID 21441120 DOI: 10.1124/Mi.11.1.6 |
0.639 |
|
| 2009 |
Prather PL, Seely KA, Levi MS. Notice of retraction. The Journal of Pharmacology and Experimental Therapeutics. 331: 1147. PMID 19940110 |
0.511 |
|
| 2009 |
Seely KA, Levi MS, Prather PL. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. The Journal of Pharmacology and Experimental Therapeutics. 330: 31-9. PMID 19359525 DOI: 10.1124/Jpet.109.151654 |
0.72 |
|
| 2007 |
Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry. 101: 87-98. PMID 17241118 DOI: 10.1111/J.1471-4159.2006.04346.X |
0.717 |
|
| Show low-probability matches. |